Denali Therapeutics, Inc. (DNLI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$19.72-5.92%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · DNLI
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||
| Revenues | — | — | — | 330.5 | 108.5 | 48.7 | 335.7 | 26.3 | 129.1 |
| Total Revenues | — | — | — | 330.5 | 108.5 | 48.7 | 335.7 | — | — |
| Operating Expenses & Income | |||||||||
| R&D Expenses | 404.9 | 418.8 | 396.4 | 423.9 | 358.7 | 265.4 | 212.6 | 193.4 | 143.2 |
| Operating Income | (532.0) | (555.3) | (487.3) | (196.7) | (340.7) | (295.8) | 62.7 | (213.2) | (46.4) |
| Earnings from Continuing Operations | |||||||||
| Other Non-Operating Income / Expenses | — | — | — | 51.5 | 14.8 | 4.6 | 9.2 | 15.2 | 10.1 |
| Income Tax Expense | — | 0.1 | 0.1 | 0.0 | 0.0 | (0.6) | 0.8 | (0.4) | — |
| Net Income | |||||||||
| Net Income | (314.4) | (512.5) | (422.8) | (145.2) | (326.0) | (290.6) | 71.1 | (197.6) | (36.2) |
| Per Share | |||||||||
| Basic EPS | (1.67) | (2.97) | (2.57) | (1.06) | (2.60) | (2.39) | 0.65 | — | — |
| Diluted EPS | (1.64) | (2.97) | (2.57) | (1.06) | (2.60) | (2.39) | 0.63 | — | — |
| Basic Weighted Avg Shares | 188.4 | 172.6 | 164.5 | 137.4 | 125.5 | 121.5 | 109.0 | — | — |
| Diluted Weighted Avg Shares | 192.1 | 172.6 | 164.5 | 137.4 | 125.5 | 121.5 | 112.7 | — | — |
| Supplemental | |||||||||
| EBITDA | — | (544.2) | (479.5) | (180.0) | (330.4) | (287.2) | 71.2 | (205.2) | (39.0) |
| EBIT | (532.0) | (555.3) | (487.3) | (196.7) | (340.7) | (295.8) | 62.7 | (213.2) | (46.4) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.